EM1809G "Hemophilia: Past, Present, and Future"
Hemophilia A and B are rare X-linked recessive bleeding disorders. Prior to the availability of safe and effective clotting factor concentrates, hemophilia resulted in early mortality from catastrophic bleeding and poor quality of life due to hemophilic arthropathy. The goal of this program is to describe the advances in hemophilia management over the last 50 years, and discuss novel therapies that are easing the burden on patients and paving the way for a possible cure in the future.
UT Southwestern faculty, fellows, residents and medical students, community physicians, nurse clinicians, physician assistants and nurses.
At the conclusion of this activity, the participant should be able to:
- Understand why hemophilia A and B lead to a bleeding diathesis.
- Understand the concept of prophylaxis and how this has changed the natural history of severe hemophilia.
- Describe strategies for managing inhibitor development.
- Explain the rationale behind novel therapies targeting natural anticoagulants.
- Describe the progress made in gene therapy that may eventually lead to a life-long cure.
Siayareh Rambally, M.D.
Assistant Professor of Internal Medicine
Division of Hematology/Oncology
- 1.00 AMA